What is the difference between Angiotensin (1-7) and Livagen?

Angiotensin (1-7): Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Livagen: Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways

Is Angiotensin (1-7) FDA approved?

Angiotensin (1-7) is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Livagen FDA approved?

Livagen is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Angiotensin (1-7) administered in research settings?

In research settings, Angiotensin (1-7) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Livagen administered in research settings?

In research settings, Livagen is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Angiotensin (1-7) vs Livagen

Peptide Comparison

Angiotensin (1-7) vs Livagen

Both are Longevity & Cellular peptides.

Angiotensin (1-7)

Ang-(1-7)

LongevityInvestigationalResearch Only

Half-life: ~9–10 sec (rat)

No providers listed yet

Full Angiotensin (1-7) profile →

Livagen

Lys-Glu-Asp-Glu

LongevityNot EvaluatedResearch Only

Half-life: Unknown

2 providers listed

Full Livagen profile →

Bottom line

Angiotensin (1-7) carries stronger published evidence (RCT, 15 key studies) than Livagen (Review, 2); both are research compounds.

Quick Verdict

Angiotensin (1-7)

Evidence

Clinical

Half-life

~9–10 sec (rat)

Livagen

Evidence

Review-level

Half-life

Unknown

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Angiotensin (1-7)
Further along in FDA review	Angiotensin (1-7)
More provider options (0 vs 2)	Livagen

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Angiotensin (1-7)

Livagen

Mechanism Family

Longevity & Cellular

Half-life

~9–10 sec (rat)

Unknown

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

subcutaneous, intramuscular

Availability

Research Only

Providers

None listed

2 listed

Avail. Notes

—

Russian liver peptide bioregulator (Lys-Glu-Asp-Gly) from Khavinson Institute. Studied for aging and hepatic function. No FDA approval, no NDA or IND. Research chemical in US.

Research Evidence

Angiotensin (1-7)

ClinicalRCT · 15 key studies · most recent 2026

Livagen

Review-levelReview · 2 key studies · most recent 2022

Research Citations

Angiotensin (1-7)

Cohort2026 · Metabolites

The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.

Cohort2026 · Res Sq

Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…

Cohort2026 · Hypertension

Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.

Cohort2026 · Front Pharmacol

Neuroprotective effects of telmisartan in a harmaline-induced model of essential tremor: modulation of the re…

+11 more

Livagen

Review2022 · International Journal of Molecular Sciences

Bioavailability and Biological Activities of Food-Derived Di- and Tripeptides: In Silico and In Vitro Studies

Review2020 · Stem Cell Reviews and Reports

Short Peptides in the Treatment of Age-Related Diseases

About Angiotensin (1-7)

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Research Areas

cardiovascular protectionanti-fibroticvasodilationinsulin sensitivitykidney protection

About Livagen

Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways

Research Areas

liver cell regenerationhepatoprotectionimmune restoration via liverchromatin activation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Angiotensin (1-7)

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Livagen

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Find Providers

Where to source these peptides

Providers offering

Angiotensin (1-7)

Browse directory →

Providers offering

Livagen

2 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.